Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06990399 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

Study acronym: PEAK
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 150 to 600v3 Show 5 more changesShow less
    • Primary completion date: Feb 2026 to Apr 2027
    • Study sites: 33 to 56
    • Study completion date: Jul 2027 to Nov 2027
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints expanded, about 6 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 33
    • Primary completion date: Dec 2026 to Feb 2026
    • Start date changed from estimate of Jul 2025 to Jul 30, 2025
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Trial Details
NCT Number NCT06990399
Lead Sponsor Kodiak Sciences Inc
Conditions
(from sponsor)		 Macular Edema Secondary to Inflammation
Related terms Macular Edema
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov